Andrew Reardon - 14 Feb 2026 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
CLO & Secretary
Signature
/s/ Andrew Reardon
Issuer symbol
LGND
Transactions as of
14 Feb 2026
Net transactions value
-$1,779,474
Form type
4
Filing time
18 Feb 2026, 16:24:47 UTC
Previous filing
12 Aug 2025
Next filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Reardon Andrew CLO & Secretary 555 HERITAGE DRIVE, SUITE 200, JUPITER /s/ Andrew Reardon 18 Feb 2026 0001950232

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +6,928 +22% $0.000000 37,739 14 Feb 2026 Direct F1
transaction LGND Common Stock Tax liability $590,278 -3,211 -8.5% $183.83 34,528 14 Feb 2026 Direct F2
transaction LGND Common Stock Award $0 +8,810 +26% $0.000000 43,338 14 Feb 2026 Direct F1
transaction LGND Common Stock Tax liability $750,578 -4,083 -9.4% $183.83 39,255 14 Feb 2026 Direct F2
transaction LGND Common Stock Tax liability $109,011 -593 -1.5% $183.83 38,662 15 Feb 2026 Direct F3
transaction LGND Common Stock Tax liability $147,248 -801 -2.1% $183.83 37,861 15 Feb 2026 Direct F3
transaction LGND Common Stock Tax liability $182,359 -992 -2.6% $183.83 36,869 15 Feb 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon the vesting and certification of performance stock units ("PSUs").
F2 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs.
F3 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.